<DOC>
	<DOC>NCT00381264</DOC>
	<brief_summary>This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis.</brief_summary>
	<brief_title>Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The purpose of this study is to determine the safety and efficacy of Cesamet™ in the symptomatic treatment of pain due to Multiple Sclerosis. This is a phase IV, multi-center, open label outpatient clinical trial evaluating Cesamet™ treatment for control of pain due MS. The study has two phases: a Pretreatment Phase and a Treatment Phase.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<criteria>Patients diagnosed with MS Chronic daily pain present for at least 2 months. On stable analgesic regimen for one month Baseline pain score greater than 40mm on a visual analog scale. Hypersensitivity to compounds in study drug or similar drugs Pregnant or lactating females Drug or alcohol abuse Unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>